# US 2025/0152598 A1 · Method for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152598 A1
- Document ID: US20250152598A1
- Status: Published application
- Kind: A1
- Application number: 18/895,046
- Filed: 2024-09-24
- Published: 2025-05-15
- Earliest claimed: 2014-10-16
- Assignees: Epizyme, Inc.
- Applicants: Epizyme, Inc.
- Inventors: Heike Keilhack
- Web page: https://patentgrep.com/patent/US20250152598A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/45: having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
- A61K 31/453: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a method for treating or alleviating a symptom of a disorder, e.g., immune evasion, cancer-cell induced immune dysfunction, reduced immune response, lowered inflammation, decreased expression of a major histocompatibility complex (MHC), or cancer, characterized by aberrant, misregulated, or increased Enhancer of Zeste Homolog 2 (EZH2) activity in a cell or subject in need thereof by contacting the cell or administering to the subject a therapeutically effective amount of an EZH2 inhibitor.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A method for treating or alleviating a symptom of a cancer in a human subject comprising administering to the human subject Compound A:
or a pharmaceutically effective salt thereof;
wherein the human is characterized by reduced expression of one or more of major histocompatibility complex (MHC), β2 microglobulin, Tumor Necrosis Factor (TNF) receptor, Low Molecular Mass Polypeptide 2, (LMP2), Low Molecular Mass Polypeptide 7, (LMP7), Transporter Associated with Antigen Processing (TAP), and TAP-associated glycoprotein (tapasin) in a cancer cell when compared to a non-cancerous cell.

### Claim 24 (depends on 23)

The method of claim 23, wherein administration of Compound A results in reduced immune evasion in a cancer cell of the human subject.

### Claim 25 (depends on 23)

The method of claim 23, wherein administration of Compound A results in treating or alleviating a symptom of cancer-cell induced immune dysfunction of the human subject.

### Claim 26 (depends on 23)

The method of claim 23, wherein administration of Compound A results in increased expression of MHC in the human subject.

### Claim 27 (depends on 23)

The method of claim 23, wherein the human subject is characterized by reduced expression of one or more MHC.

### Claim 28 (depends on 27)

The method of claim 27, wherein MHC is human leukocyte antigen (HLA), wherein the HLA is selected from the group consisting of HLA-A, HLA B, HLA-C, HLA DM alpha, HLA DM beta, HLA-DO alpha, HLA DO beta 1, HLA DP alpha 1, HLA DP beta 1, HLA DR alpha, HLA-DR beta 1, HLA-DR beta 3, HLA DR beta 4, HLA E, HLA F, HLA G, HLA K, and HLA L.

### Claim 29 (depends on 23)

The method of claim 23, comprising administering to the human subject Compound A:

### Claim 30 (depends on 23)

The method of claim 23, comprising administering to the human subject a pharmaceutically acceptable salt of Compound A:

### Claim 31 (depends on 30)

The method of claim 30, wherein the pharmaceutically acceptable salt is a hydrobromic acid salt.

### Claim 32 (depends on 23)

The method of claim 23, wherein the human subject comprises aberrant, misregulated, or increased EZH2 activity.

### Claim 33 (depends on 29)

The method of claim 29, wherein the human subject comprises aberrant, misregulated, or increased EZH2 activity.

### Claim 34 (depends on 31)

The method of claim 31, wherein the human subject comprises aberrant, misregulated, or increased EZH2 activity.

### Claim 35 (depends on 23)

The method of claim 23, wherein the human subject comprises a chromosomal translocation t(x;18)(p11.2; q11.2).

### Claim 36 (depends on 35)

The method of claim 35, wherein the translocation causes a SS18-SSX fusion gene.

### Claim 37 (depends on 29)

The method of claim 29, wherein the human subject comprises a chromosomal translocation t(x;18)(p11.2; q11.2).

### Claim 38 (depends on 37)

The method of claim 37, wherein the translocation causes a SS18-SSX fusion gene.

### Claim 39 (depends on 31)

The method of claim 31, wherein the human subject comprises a chromosomal translocation t(x;18)(p11.2; q11.2).

### Claim 40 (depends on 39)

The method of claim 39, wherein the translocation causes a SS18-SSX fusion gene.
